目的探讨依那普利联合人胰岛素治疗糖尿病肾病的临床疗效。方法随机将在本院进行治疗的84例糖尿病肾病患者分成治疗组与对照组,每组42例,治疗组在常规治疗的基础上采取依那普利联合人胰岛素进行治疗,对照组在常规治疗的基础上采取缬沙坦联合口服降糖药进行治疗,治疗后3个月、6个月后分别监测2组患者的血压、空腹血糖(FBG)、餐后2 h血糖(PBG)、糖化血红蛋白(Hb Alc)及尿素氮(BUN)、肌酐(Scr)、白蛋白(ALB)及低血糖发生率。结果治疗后3个月,治疗组低血糖发生率为9.52%,对照组为7.14%;治疗后6个月,治疗组低血糖发生率为7.14%,对照组为2.38%。治疗前2组的FBG、PBG、Hb Alc、BUN、Scr、ALB相比差异无统计学意义(P>0.05)。治疗后3个月、6个月,治疗组的FBG、PBG、Hb Alc、BUN、Scr明显低于对照组(P<0.01)结论依那普利联合人胰岛素治疗糖尿病肾病临床疗效明显,延缓肾功能恶化,可在临床中推广应用。 Objective To investigate the clinical efficacy of enalapril combined with insulin in the treatment of diabetic nephropathy. Methods A total of 84 patients with diabetic nephropathy who were treated in our hospital were randomly divided into treatment group and control group with 42 cases in each group. The treatment group was treated with enalapril combined with human insulin on the basis of routine treatment, while the control group received conventional therapy The patients were treated with valsartan combined with oral hypoglycemic agents. The blood pressure, fasting blood glucose (FBG), postprandial blood glucose (PBG), hemoglobin A1c Hb Alc, BUN, Scr, ALB and incidence of hypoglycemia. Results The incidence of hypoglycemia was 9.52% in the treatment group and 7.14% in the control group at 3 months after treatment. The incidence of hypoglycemia in the treatment group was 7.14% at 6 months and 2.38% in the control group. There were no significant differences in FBG, PBG, Hb Alc, BUN, Scr and ALB between the two groups before treatment (P> 0.05). The levels of FBG, PBG, Hb Alc, BUN and Scr in the treatment group were significantly lower than those in the control group at 3 months and 6 months after treatment (P0.01) .Conclusion Enalapril combined with human insulin has obvious clinical curative effect on diabetic nephropathy, Functional deterioration, can be widely used in clinical practice.